Neuromyelitis Optica Spectrum Disorder (NMOSD): Clinical Features, Diagnosis, and Treatment

Neuromyelitis optica spectrum disorder (NMOSD), formerly Devic disease, is an autoimmune astrocytopathy targeting aquaporin-4 (AQP4) water channels on astrocytes. It is distinct from multiple sclerosis (MS) and requires specific immunotherapy to prevent devastating relapses.

Pathophysiology

  • AQP4-IgG (NMO-IgG): Pathogenic autoantibody in 70–80% of NMOSD. Binds astrocytic AQP4 → complement activation (CDC), antibody-dependent cellular cytotoxicity (ADCC), granulocyte infiltration → astrocyte loss, demyelination, neuronal injury.
  • Seronegative NMOSD: ~20–30%; some have anti-MOG antibodies (MOGAD — distinct entity), others truly double-seronegative.

Core Clinical Characteristics (2015 IPND Criteria)

Diagnosis requires ≥1 core characteristic + AQP4-IgG positivity, or ≥2 core characteristics (one must be optic neuritis, acute myelitis, or area postrema syndrome) + MRI requirements if seronegative.

  1. Optic neuritis: Typically bilateral, severe, longitudinally extensive (involving >1/2 optic nerve), chiasmal involvement common. Poor recovery without treatment.
  2. Acute myelitis: Longitudinally extensive transverse myelitis (LETM) — ≥3 vertebral segments. Central cord involvement. Flaccid paralysis, sensory level, autonomic dysfunction (neurogenic bladder/bowel).
  3. Area postrema syndrome: Intractable nausea, vomiting, hiccups (dorsal medulla). Often presenting feature.
  4. Acute brainstem syndrome: Periaqueductal lesions → oculomotor, vestibular, respiratory centers.
  5. Symptomatic narcolepsy / diencephalic syndrome: Hypothalamic lesions.
  6. Symptomatic cerebral syndrome: Large hemispheric lesions (unlike MS).

Diagnostic Workup

  • Serum AQP4-IgG: Cell-based assay (gold standard). ELISA has high false-positive rate.
  • MRI Brain/Orbits/Spine: LETM, optic nerve T2 hyperintensity >1/2 length, periependymal brain lesions (area postrema, hypothalamus, brainstem).
  • CSF: Pleocytosis (often >50 WBC, neutrophilic), elevated protein, low glucose (unlike MS). Oligoclonal bands rare (<20%).
  • MOG-IgG: Rule out MOGAD (better prognosis, different treatment).

Acute Relapse Management

  • High-dose IV methylprednisolone: 1g daily ×3–5 days — first-line.
  • Plasma exchange (PLEX): 5–7 exchanges if incomplete response to steroids — critical for severe myelitis/ON. Early initiation (<2 weeks) improves outcomes.
  • IVIG: Alternative if PLEX unavailable/contraindicated.

Long-Term Immunosuppression (Relapse Prevention)

All AQP4+ patients require maintenance therapy. Relapse risk high without treatment; each relapse causes cumulative disability.

  • Eculizumab (Soliris): Anti-C5 complement inhibitor; FDA-approved 2019. IV q2wk. Reduces relapse risk >90%. Meningococcal vaccination required.
  • Satralizumab (Enspryng): Anti-IL-6 receptor; SC q4wk. FDA-approved 2020. Effective in AQP4+.
  • Inebilizumab (Uplizna): Anti-CD19 B-cell depletion; IV q6mo. FDA-approved 2020.
  • Rituximab: Anti-CD20; off-label but widely used, extensive real-world data. IV q6mo. Monitor IgG, B-cells.
  • Azathioprine / Mycophenolate / Tocilizumab: Older agents, less robust evidence, used if newer agents inaccessible.

Symptomatic Management

  • Neuropathic pain: gabapentin, pregabalin, duloxetine
  • Spasticity: baclofen, tizanidine, botulinum toxin
  • Bladder/bowel: anticholinergics, clean intermittent catheterization
  • Fatigue: amantadine, modafinil, energy conservation
  • Depression/anxiety: SSRIs, counseling

Prognosis

Without treatment: 50% wheelchair-bound or blind at 5 years. With modern immunosuppression: relapse-free survival >80% at 2–3 years. Early diagnosis and AQP4-targeted therapy are transformative.

Key Differentiators from MS

FeatureNMOSDMS
AntibodyAQP4-IgGNone specific (OCB+)
Optic neuritisBilateral, severe, LETMUnilateral, mild-moderate
MyelitisLETM (≥3 segments)Short segment (<3)
Brain MRIPeriependymal, hypothalamicPeriventricular, juxtacortical
CSF OCBsRareCommon (>90%)

Eye & Vision Disorders - Related Articles